Nebenwirkungen · Vevzuo
Vevzuo 120 mg solution for injection · Abschnitt 4.8 · PDF-Seite 8
HOS-153315 · Präparat HOS-100962
A non-randomised, retrospective, observational study in 2,877 patients with cancer treated with denosumab or zoledronic acid in Sweden, Denmark, and Norway showed that 5-year incidence proportions of medically confirmed ONJ were 5.7% (95% CI: 4.4, 7.3; median follow up time of 20 months [range 0.2-60]) in a cohort of patients receiving denosumab and 1.4% (95% CI: 0.8, 2.3; median follow up time of 13 months [range 0.1-60]) in a separate cohort of patients receiving zoledronic acid. Five-year incidence proportion of ONJ in patients switching from zoledronic acid to denosumab was 6.6% (95% CI: 4.2, 10.0; median follow up time of 13 months [range 0.2-60]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-17T09:08:00Z · SHA-256 62447120a0dd72ad6043dd799725298b12ec6ff2c23546d2a5f4d3312480e3d3 · Passage eb683bf7d86f468a17c2bb1b28e7fc500612b850e4907fef80924a313e48c4bf · Zeichen 7808–8469 im Abschnitt